Avita Medical
1st Floor, Unex House
132-134 Hills Road
Cambridge
CB2 8PA
United Kingdom
Tel: 44-0-1223 341150
Fax: 44-0-1223-341170
Website: http://www.avitamedical.com/
Email: info.eu@avitamedical.com
276 articles about Avita Medical
-
Breakthrough Medical and Pharmaceutical Funding Awarded to Consortium That Partners Avita Medical With 20 Other Organisations Across Australia
10/27/2017
Regenerative skin company Avita Medical is delighted to be part of Accelerating Australia, a consortium that will inject up to $2 million into a breakthrough innovation project designed to commercialise big ideas.
-
Avita Medical Taps Investors for A$16.9 Million to Commercialise Its 'Spray-On Skin'
10/11/2017
-
Avita Medical Release: U.S. FDA Approves New Continued Access Protocol For The ReCell Device For Treatment Of Burn Injuries
10/4/2017
-
Avita Medical Announces Submission Of U.S. FDA Premarket Approval (PMA) Application For The Recell Device For Treatment Of Burn Injuries
9/28/2017
-
Avita Medical And BARDA Execute A $24.3 Million Contract Option
9/21/2017
-
Avita Medical Release: Research Definitively Confirms Superiority Of ReCell For Treatment Of Burn Injuries
9/12/2017
-
Avita Medical Names Erin Liberto As Chief Commercial Officer
8/31/2017
-
Avita Medical CEO Issues Shareholder Letter
7/13/2017
-
Avita Medical Release: New Randomized Trial Shows Recell Heals Donor Sites Faster
6/20/2017
-
Avita Medical Taps Former Novartis AG Exec as New CEO
6/2/2017
-
Avita Medical 's Board Show Confidence in Company By Taking Payment In Shares
5/23/2017
-
Avita Medical Announces Positive Results From Pivotal Trial
5/18/2017
-
Avita Medical Initiates Legal Proceedings To Cancel Renovacare Patent
5/11/2017
-
Avita Medical Release: Initial Pre-Emergency Use Authorization Submission Made To U.S. FDA For Use Of ReCell In A Mass Casualty Scenario
5/10/2017
-
Avita Medical Release: Initial Pre-Emergency Use Authorization Submission Made To U.S. FDA For Use Of ReCell In A Mass Casualty Scenario
5/10/2017
-
Avita Medical CEO Shareholder Letter And Quarterly Report
4/28/2017
-
Avita Medical Release: FDA Approves Increased Compassionate Use Patient Cases And Sites For Recell In Life-Threatening Injuries
4/7/2017
-
Avita Medical Announces Receipt Of $975K R&D Tax Incentive
3/16/2017
-
Avita Medical Announces Last Patient Visit In U.S. Pivotal Trial
3/7/2017
-
Avita Medical 's ReCell Devices Now Treating Burns In South Africa And Benelux
10/20/2016